Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
361-380 of 1,743 trials

Heart Failure: Stopping Medication After Cardiac Resynchronization Therapy

We are studying the effects of withdrawing medication in patients who have improved heart function after cardiac resynchronization therapy. This trial will help us understand the safety and changes in heart health when treatment is stopped.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCardiologyInternal Medicine

HER2-Positive Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan Study

We are investigating a new treatment combining Trastuzumab Deruxtecan with immunotherapy and chemotherapy for patients with advanced HER2 over-expressing Non-Small Cell Lung Cancer. The study aims to evaluate the safety and tolerability of this approach.

HER2 Positive Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Triple-Negative Breast Cancer: MK-2870 with Pembrolizumab

We are studying a new treatment combining MK-2870 and pembrolizumab for people with triple-negative breast cancer who had surgery but did not respond completely. The trial aims to see if this combination works better than standard treatment options.

Triple Negative Breast Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cervical Cancer: Surgery Plus Therapy Study

We are investigating whether additional therapy after surgery helps patients with early-stage, intermediate-risk cervical cancer stay cancer-free. This study compares outcomes with and without further treatment.

Early-Stage Cervical Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Surgical Site Infection Prevention: Linezolid vs. Vancomycin

We are studying whether linezolid is as effective as vancomycin in preventing infections after surgery. This trial includes various surgeries and looks at infection rates and patient experiences.

Surgical Antibiotic Prophylaxis>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

Quizartinib for Pediatric FLT3-ITD Positive AML

We are studying the safety and effectiveness of quizartinib combined with chemotherapy in children and adolescents newly diagnosed with FLT3-ITD positive acute myeloid leukemia. This trial aims to see if it helps improve treatment outcomes compared to standard therapies.

Pediatric Acute Myeloid Leukemia (AML)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Prostate Cancer: New Treatment Combining Radiation and Antiandrogen

We are studying a new treatment approach for men with advanced prostate cancer to see if combining radiation therapy with a second-generation antiandrogen improves outcomes. The trial will also look at quality of life and any side effects from the treatment.

Oligometastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Non-Seminomatous Germ-Cell Tumors: Personalized Treatment Study

We are exploring new treatment strategies for young adults with poor-prognosis non-seminomatous germ-cell tumors. This study aims to improve outcomes through personalized care and early assessments.

Germ Cell Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Long-Term Study of Delandistrogene Moxeparvovec (SRP-9001)

We are assessing the long-term safety and effectiveness of delandistrogene moxeparvovec in individuals who previously participated in a clinical study. This research aims to understand how the treatment continues to affect participants over time.

Duchenne Muscular Dystrophy>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

Spironolactone for Arrhythmogenic Right Ventricular Dysplasia (ARVD)

We are studying whether spironolactone can help reduce heart deterioration and arrhythmias in patients with ARVD. This trial compares its effects to a placebo over one and three years.

Arrhythmogenic Right Ventricular Dysplasia>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Multiple Myeloma: HyQvia for Infection Prevention

We are studying whether HyQvia can help reduce infections in patients with newly diagnosed multiple myeloma who are not eligible for a transplant. The trial aims to see if it improves survival and quality of life compared to standard care.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyInfectious Diseases

Lung Cancer Treatment Comparison: Atezolizumab vs. Pembrolizumab

We are studying two treatment combinations for patients with metastatic TTF-1 negative lung adenocarcinoma to see which one may improve survival. This trial compares atezolizumab with carboplatin and nab-paclitaxel against pembrolizumab with platinum and pemetrexed.

Metastatic Lung Adenocarcinoma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyPulmonology

Juvenile Idiopathic Arthritis: Upadacitinib Study

We are evaluating the safety and how the body processes upadacitinib in children with polyarticular course juvenile idiopathic arthritis. The study also examines how well children tolerate the medication and its taste.

Juvenile Idiopathic Arthritis>2 yearsSafety phase (I)Post-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsRheumatology

Preclinical Alzheimer's Disease: JNJ-64042056 Immunotherapy

We are studying a new treatment to see if it may help slow cognitive decline in people with preclinical Alzheimer's disease. Participants will receive either the treatment or a placebo to compare effects.

Preclinical Alzheimer's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesNeurologyPsychiatry

Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease

We are studying whether tocilizumab can help patients with sickle cell disease recover from acute chest syndrome faster and safely. The trial includes both children and adults to assess its effectiveness and safety.

Sickle Cell Disease>2 yearsConfirmation phase (III)Standard MedicinesHematologyPulmonology

Uveitis Treatment: Adalimumab vs. Mycophenolate Mofetil

We are studying whether adalimumab can improve outcomes for people with steroid-dependent non-infectious uveitis compared to the standard treatment. This trial will help us understand the effectiveness and safety of both medications.

Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmologyRheumatology

Spinal Muscular Atrophy: Risdiplam for Children

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have not improved after gene therapy. This research aims to see if risdiplam can help these patients regain function.

Spinal Muscular Atrophy (SMA)>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Metastatic Colorectal Cancer: Targeted Therapies Study

We are evaluating the safety and effectiveness of new targeted treatments for patients with metastatic colorectal cancer. This study aims to find better options for specific groups of patients.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Oncology

Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab with Chemotherapy

We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.

Resectable Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteOncology

Combination Therapies for Advanced Esophageal Cancer

We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.

Advanced Esophageal Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteOncology